D&A
Flow – sum over the period · $M
Q2 2026
3.9$M
All values (10)
| Period | Value ($M) | Status |
|---|---|---|
| Q2 2026 | 3.9 | reported |
| Q1 2026 | 3.7 | reported |
| Q4 2025 | 2.8 | derived |
| Q3 2025 | 1.5 | reported |
| Q2 2025 | 1.4 | reported |
| Q1 2025 | 1.1 | reported |
| Q4 2024 | 1.0 | derived |
| Q3 2024 | 0.8 | reported |
| Q2 2024 | 0.7 | reported |
| Q1 2024 | 0.6 | reported |
| Q1 2016 – Q4 2023 | – | missing (32 periods): No verified SEC value extracted, although the company reports this metric in other periods. |
Show reported periods only · CSV with all sources · Technical ID: dna
More metrics for Astera Labs
Income statement
Balance sheet
Revenue by segment/product/region
Sources & calculation
- Value
- $4.0M
- Period
- Q2 2026, ended Jun 30, 2026 · quarterly value (3 months, not cumulative)
- Source
- 10-Q, filed Aug 5, 2026 · 0001736297-26-000035
- Location
- us-gaap:DepreciationDepletionAndAmortization
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $4.0M | Aug 5, 2026 | 10-Q 0001736297-26-000035 | reported · confidence 1. · current |